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Abstract
The treatment of zygomycosis has two cornerstones, namely, surgery and antifungal drugs. In many patients, both need to be applied to
achieve treatment success; without treatment, the mortality rate of zygomycosis approaches 100%. Because treatment options are lim-
ited, no well-designed randomized clinical trial has been conducted and data are predominantly derived from compassionate-use pro-
grammes or case reports. Amphotericin B (AmB) lipid complex (ABLC) was clinically evaluated for efﬁcacy against zygomycosis in a
single series and resulted in cure or improvement in 52% and in the stabilizing of disease in 20% of patients. Liposomal AmB (L-AmB) is
frequently used, but no large series have yet been published. Posaconazole has demonstrated in vitro and in vivo activity against Zygomy-
cetes. Two series demonstrated salvage treatment response rates of 60% and 79%, respectively. Antifungal combinations have not been
evaluated thoroughly enough to warrant recommendations outside of clinical trials. Survival is usually associated with surgical debride-
ment and improvement in underlying diseases. Currently, surgical debridement should be performed. Antifungal treatment should con-
sist of either ABLC ‡5 mg/kg once per day or L-AmB ‡3 mg/kg once per day. When toxicity occurs or stable fungal disease is
achieved, treatment can be switched to oral posaconazole 200 mg four times per day. If impaired kidney function is overt or expected
on the grounds of, for example, uncontrolled diabetes, primary treatment of zygomycosis with posaconazole is an option.
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Introduction
Zygomycoses are the most common of the so-called ‘rare’
invasive fungal infections [1]. They represented >7% of such
diseases in a large cohort of adult haematopoietic stem cell
recipients [2].
Without treatment, the mortality rate of zygomycosis
approaches 100% [3]. For mould infections as devastating as
zygomycosis, it may even be reasonable to deﬁne the stabi-
lizing of disease as indicative of successful treatment [4].
Zygomycetes are ubiquitous organisms. Although the most
severely immunocompromised patients are most at risk,
other patient populations are too. These populations are
heterogeneous and range from patients with poorly
controlled diabetes mellitus to those with contaminated
traumatic wounds [5,6]. Peritoneal dialysis is another risk
factor, in which zygomycetes peritonitis should be included
in a differential diagnosis. An overview of cases published has
recently been presented [7]. Nosocomial outbreaks related
to construction work have been described, as have
outbreaks caused by water damage within the rooms of a
paediatric oncology ward, which led to two invasive
infections and required control with an aggressive mana-
gement plan [8].
Treatment Options for Zygomycosis
Although therapeutic options for invasive aspergillosis and
invasive candidiasis have increased during the last decade,
treatments for diseases caused by Zygomycetes remain
very limited [9]. In general, four therapeutic options
deserve consideration as part of a multimodal approach to
therapy. One approach involves surgery and the other
three rely on the different antifungal drugs that show
activity against Zygomycetes. Most patients undergo surgical
debridement, frequently prior to diagnosis of the nature of
the infection. Extensive surgical debridement is difﬁcult to
achieve because important structures are often adjacent to
necrotic tissues, particularly in sinu-nasal, rhino-orbital and,
especially, cerebral involvement. As a consequence, surgery
may at best yield a partial remission [4]. Some well-docu-
mented cases describe fungal organisms in repeat histology
ª2009 The Authors
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samples over substantial periods of time [10]. The available
antifungal treatments which are active against Zygomycetes
include amphotericin B (AmB) in its various formulations
and posaconazole. Of the polyene formulations, AmB lipid
complex (ABLC) has been clinically evaluated for efﬁcacy
against zygomycosis in two series. In one, an emergency-
use programme for salvage treatment described a complete
and partial response rate of 71% [11]. In the other, using
post-marketing data (n = 64) with a median daily dose of
4.8 mg/kg, cure or improvement occurred in 52% and
stable disease in another 20% of patients [12]. Liposomal
AmB (L-AmB) is frequently used, but prospective series of
patients have rarely been published. However, a multivari-
ate analysis characterized L-AmB treatment as the single
prognostic factor correlating with recovery from infection
[13].
Use of Posaconazole Against Zygomycetes
Infections
Posaconazole has in vitro and in vivo activity against Zygomy-
cetes. The properties of posaconazole have been thoroughly
described elsewhere [14]. In general, posaconazole is consid-
ered a safe drug, even when given over long periods of time
[15].
Two series have been published. The ﬁrst (n = 24)
reported on two non-randomized compassionate-use pro-
grammes evaluating salvage treatment with posaconazole oral
suspension 200 mg administered four times per day or
400 mg administered twice per day. The infections were rhi-
nocerebral in 46% of cases and the median treatment dura-
tion was 182 days. The overall rate for complete and partial
response was 79% and was similar in both patients with
refractory disease and those with intolerance to standard
therapy. The survival rate was 79% and was associated with
surgical debridement and improvement in underlying dis-
eases. Posaconazole oral solution was generally well toler-
ated [16]. The second publication reported on a higher
number of patients (n = 91) in a compassionate-use pro-
gramme. Its data were retrospectively analyzed. All patients
were treated with a dose of 800 mg/day administered in two
or four doses. Eleven patients from the previous report
were included. Of the patients, 76% had proven and 24%
had probable invasive infection, and 89% were refractory
towards previous treatment. The overall rate of complete or
partial response was 60% at 12 weeks. An additional 21% of
patients achieved stable disease [17].
More than 20 case reports of posaconazole salvage treat-
ment have been published (Table 1). Common to almost all
is a complete response in severely ill patients. There may be
some overlap with the two larger series described above
[16,17] and some publication bias towards the reporting of
cases with favourable outcomes is likely to have occurred.
However, the published results are encouraging and warrant
further evaluation of the role of posaconazole in treating
zygomycosis.
Proposal for a Combined Treatment
Approach for Zygomycosis
Currently, all the treatment options described should be
considered for patients with zygomycosis. A recommended
treatment plan is shown in Fig. 1. Surgical debridement
should be used to the extent feasible to reduce the fungal
burden. Medical treatment should rely on ABLC at a daily
dose of ‡5 mg/kg or L-AmB at a daily dose of ‡3 mg/kg. In
cases of toxicity or treatment failure, switching to oral posa-
conazole, 200 mg four times per day, is an effective second-
line option. Treatment with posaconazole also appears to
facilitate the discharge of patients who achieve at least stable
disease.
Invasive
zygomycosis 
Surgical debridement
Normal renal
function
Amphotericin B lipid complex
(ABLC) >5 mg/kg QD iv
or
Liposomal amphotericin B
>3 mg/kg QD iv
Impaired renal
function
Posaconazole
200 mg QID po
Failure/intolerance
or
Stable disease and
discharge intended
FIG. 1. Recommended treatment options for patients with zygomy-
cosis.
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Conclusions
If impaired kidney function is overt or expected on grounds
of long-term uncontrolled diabetes mellitus or substantially
elevated HbA1c results, primary treatment of zygomycosis
with posaconazole 200 mg four times per day is a reasonable
option. Antifungal combinations have not been evaluated
thoroughly enough to warrant their recommendation outside
the clinical trial setting.
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